LAVA Therapeutics (NASDAQ:LVTX) just reported results for the first quarter of 2024.
- LAVA Therapeutics reported earnings per share of -2 cents. This was above the analyst estimate for EPS of -12 cents.
- The company reported revenue of $6.99 million.
- This was 0.11% worse than the analyst estimate for revenue of $7.00 million.